Clinical Trial Update: OPTIMUS PRIME: Safety and Feasibility of OPTune GIO® Integrated With MRI-gUided Laser Ablation Surgery and Pembrolizumab for Recurrent GlIoblastoMa, A randomizEd Trial [Phase 2]

View source ↗

Summary

A Phase 2 randomized trial assessing the combination of OPTune GIO (tumor treating fields device) with MRI-guided laser ablation and pembrolizumab for recurrent…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• OPTune GIO
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: University of Florida | Conditions: Recurrent Glioblastoma | Phase 2 | Status: RECRUITING